CARLSBAD, Calif.--(BUSINESS WIRE)--Regulus Therapeutics Inc. announced today that the United States Patent and Trademark Office (USPTO) has allowed claims in U.S. Application Serial No. 11/977,506 covering methods of antagonizing miR-181a to regulate immune response. This patent is owned by Stanford University and licensed exclusively to Regulus. miR-181a has been shown to regulate the response of immune cells, such as T lymphocytes, to specific stimuli and modulation of miR-181a could lead to a novel treatment of inflammatory disease.
